Item 1.01. Entry into a Material Definitive Agreement.
The Registrant intends to use the proceeds of the offering primarily for the development of the Trappsol® Cyclo™ orphan drug, including submission of a Drug Master File with the
This summary of the Agreement is qualified in its entirety by reference to the Agreement attached as an exhibit to this report.
This report contains "forward-looking statements" about the Registrant's current plans and expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as statements pertaining to the Registrant's regulatory and other plans for its Trappsol® Cyclo™ product, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Registrant's future performance include its ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Registrant's filings with the
- 2 -
Item 3.02 Unregistered Sales of
The information set forth above under Item 1.01 is incorporated into this Item 3.02 by reference. The Shares were issued in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of the private placement exemption in section 4(a)(2) of that Act and/or the provisions of Regulation D promulgated thereunder.
Item 7.01 Regulation FD Disclosure
Item 9.01 Financial Statements and Exhibits
10.1 Securities Purchase Agreement dated as of
CTD Holdings, Inc.and the purchasers named therein
99.1 Press release dated
- 3 -